Vitara Biomedical is dedicated to transforming neonatal care, particularly for premature infants who face significant physiological challenges at birth. The company is developing a next-generation platform therapy aimed at providing a stable and comfortable environment for these vulnerable newborns, allowing them to acclimate to life outside the womb while continuing their development. This innovative approach addresses the critical issue of premature birth, which is a leading cause of mortality in children under five, by focusing on the unique needs of infants whose lungs may not be fully developed at birth.

In addition to their neonatal solutions, Vitara Biomedical is also advancing the Velocity™ pAVF System, a cutting-edge technology designed to enhance vascular access outcomes for patients requiring hemodialysis. This system aims to reduce the need for reinterventions by promoting faster maturation of arteriovenous fistulas (AVFs), thereby improving functionality and reducing overall costs. The Velocity System's emphasis on achieving ideal AVF hemodynamics positions it as a competitive solution in the field, showcasing Vitara's commitment to innovation in both neonatal and vascular care.

United States

At Vitara, we are working to offer preterm newborns and their families a lifetime of possibilities. We seek to transform neonatal care by protecting more preterm infants and improving their quality of life.

Vitara Biomedical

Company Details